mice. Stable MCF7-PAR1 clones were isolated and that MMPs are largely expressed by the stromal fibrotested for PAR1 surface expression by FACS. Clone blast and inflammatory cells recruited to the tumor N55 was found to express high levels of PAR1, similar (Heppner et al., 1996) .
to MDA-MB-231 cells (Kamath et al., 2001), and miHere, we show that expression of PAR1 in breast cargrated 16-fold and invaded 30-fold faster through matcinoma cells is sufficient to promote growth and invarigel relative to the parental MCF-7 cells (data not sion of xenografts in nude mice. We demonstrate that shown). MCF7-PAR1/N55 and the MCF-7 control (PAR1 the presence of functional PAR1 accounts for the manull) parental cell line were injected into the left and jority of the invasive signal in breast cancer cells. We right mammary fat pads, respectively, of female 6-to identify the matrix metalloprotease, MMP-1, to be a 7-week-old athymic NCR nu/nu mice ( Figure 1C ). Tunovel protease agonist that cleaves PAR1 at the proper mors developed only in mice injected with MCF7-site for receptor activation and generates PAR1-depen-PAR1/N55 (9/9), and there was no detectable tumor fordent Ca 2+ signals and migration. Targeting Figure S1A ). In contrast, PAR1. MCF-7 cells transiently expressing PAR1 exhibthere was no detectable tumor formation by the PAR1 ited a 3.6-fold increase in migration ( Figure 1A ) and a null MCF-7 cells, and mammary pads had normal mor-4.3-fold increase in invasion ( Figure 1B) Figures 1A and 1B , nude mice models (Kang et al., 2003) . Indeed, xenotransfection of MCF-7 cells with F43A PAR1 promoted grafts formed by MDA-MB-231 (10/10) grew more than neither cell migration nor invasion, supporting the hy-2-fold faster relative to the N55 cells and had already pothesis that PAR1 must be able to be activated for begun to invade into the abdominal muscle wall by PAR1-dependent migration and invasion to occur. week 6 ( Figure 1D and Supplemental Figure S1A ). We then tested whether knockdown of PAR1 gene expres- In addition, we tested a C-terminal i3 loop pepducin, P1pal-7, which is a full antagonist of PAR1-G protein signaling (Supplemental Figure S2 ). As shown in Figure 3A , the P1pal-12 and P1pal-7 pepducins gave similar inhibitory fractions were assayed for ability to promote migration of the MDA-MB-231 cells. We found that the promigraIdentification of MMP-1 in Media from CRL-2076 Fibroblasts tory activity separated into a major peak (fractions 3-6) and a minor peak (fractions 13-18) ( Figure 5B ). The Using RT-PCR, we confirmed that CRL-2076 fibroblasts express mRNA encoding MMP-1 ( Figure 5A ). CRL-2076 chemotactic activity of fractions 3-6 peaked at a relative molecular mass of 55 kDa and together accounted cells also express mRNA for MMP-2 and very low levels of MMP-9 mRNA. ELISA and collagenase analyses indifor 55% of the total chemoattractive activity of the loaded material and was blocked by the MMP inhibitor cated that MMP-1 levels were 34 ± 8 ng/ml (0.6 ± 0.2 nM) and MMP-2 levels were 22 ± 9 ng/ml (0.3 ± 0.1 nM) MMP-200 (data not shown). ELISA assays were conducted in order to confirm that MMP-1 was present in in the CRL-2076 fibroblast media. Similarly, NIH-3T3 media contained 0.6-1.0 nM MMP-1 collagenase activthe higher molecular mass peak of chemotactic activity. As shown in Figure Figure 6A) . Indeed, we demonstrated that treatment of the COS7 determined whether the MMP-1 levels were elevated in the N55 tumors relative to control mammary pads. N55 cells with 5 nM MMP-1 resulted in 50% loss of the T7-epitope while leaving the SFLLRN epitope intact. Simitumors were harvested from untreated mice at week 6 and examined for MMP-1 mRNA expression and collalarly, treatment of the T7-PAR1 COS7 cells with 0.5 nM thrombin caused 55% loss of the T7 epitope with retengenase activity. As shown in Figure 7A , murine MMP-1 mRNA was induced 2-fold relative to control mammary tion of the SFLLRN epitope. Treatment with NIH-3T3 media caused 30% loss of the T7 epitope, similar to fat pads. Collagenase activity was enhanced 4-fold in the N55 tumors relative to mammary fat pads ( Figure 7B ). 0.25 nM thrombin. In contrast, 5 nM concentrations of MMP-2, MMP-3, MMP-7, and MMP-9 gave little cleavThe collagenase activity in the N55 tumors was inhibited by 50% upon addition of the selective MMP-1 antagoage of COS7-expressed T7-PAR1 either to the N-or C-terminal side of the SFLLRN epitope ( Figure 6A) . nist, MMP Inh-1 (Odake et al., 1994), with no effect on the collagenase activity in the control fat pads, which These cleavage experiments demonstrate that PAR1 is cleaved at the appropriate site by MMP-1 but is not demonstrates that MMP-1 expression and MMP-1 collagenase activity are enhanced in the PAR1-expressing readily cleaved by MMP-2, -3, -7, or -9.
To directly elicit a functional MMP-1-dependent N55 breast tumors. To provide direct evidence that MMP-1 was essential PAR1 response on the surface of breast cancer cells, we conducted Ca 2+ flux measurements of the MCF7-for the tumorigenicity of the PAR1-dependent tumors, we compared the effects of pharmacologic blockade of PAR1/N55 cells. Addition of 5 nM MMP-1 to N55 cells gave 50% of the Ca 2+ peak height relative to 0.5 nM PAR1 versus MMP-1 on the growth of the N55 breast cancer xenografts. To block PAR1, we used the cellthrombin but gave a similar total integrated (area) Ca 2+ response ( Figure 6B) . Challenge of the N55 cells with penetrating i3 loop PAR1 pepducin antagonist, P1pal-7. MCF7-PAR1/N55 cells were injected into the mammary 15 nM MMP-1 gave a robust Ca 2+ response that was completely blocked by the PAR1-selective antagonist fat pads and the mice treated two days later (to allow implantation) with either vehicle or P1pal-7 (10 mg/kg RWJ-56110. None of the other MMPs that were tested (15 nM MMP-2, MMP-3, MMP-7, MMP-8, or MMP-9) s.c. every other day) for 6 weeks. As shown Figure 7C , by the 6 week time point, P1pal-7 significantly inhibited were able to elicit a Ca 2+ signal from the N55 cells. (62%) the growth of the MCF7-PAR1/N55 xenografts. The P1pal-7 pepducin treatment was well tolerated by The Therapeutic Potential of Targeting PAR1 versus MMP-1 on the Growth and the mice with no observable toxicity. We then treated the mice with MMP Inh-1 for 6 weeks and measured
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We have demonstrated that the presence of PAR1 protumor growth. Quite strikingly, MMP Inh-1 treatment of the N55 mice gave 82% inhibition of tumor growth (Figmotes tumor growth and invasion; however, we have 
